ArticleCancer reports (Hoboken, N.J.)2025
Synchronous Melanoma and Follicular Lymphoma in the Same Nodal Basin: A Diagnostic and Therapeutic Challenge.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe incidence of both malignant melanoma (MM) and non-Hodgkin lymphoma (NHL) has risen in recent decades, with studies suggesting a potential bidirectional association. Nonetheless, synchronous presentation of active disease in both entities remains rare. CASE: We report the case of a 62-year-old man with a history of indolent B-cell lymphoma, exhibiting features between marginal zone and follicular subtype, previously treated with R-CHOP, radiotherapy, and Rituximab maintenance, achieving complete remission. Ten years later, he developed an ulcerated superficial spreading melanoma (Breslow thickness 4.5 mm, pT4b), with staging CT revealing right axillary lymphadenopathy. Biopsy confirmed relapsed follicular lymphoma. Surgical management included wide excision and sentinel lymph node biopsy, which identified melanoma metastasis in one sentinel node and confirmed FL in the non-sentinel node. Molecular testing showed a BRAFV600E mutation. The patient received axillary radiotherapy followed by adjuvant BRAF/MEK inhibitor therapy.
conclusionAt 6-month follow-up, imaging showed no evidence of relapse. This represents the first documented case of synchronous stage III BRAF-mutated MM and FL managed with targeted BRAF/MEK inhibitors combined with localized radiotherapy. The successful outcome validates this sequential multidisciplinary approach and underscores the importance of dermatologic surveillance in NHL survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.